Scarica l'app Stockscreener
18.17
2.77%
0.49
Dopo l'orario di chiusura:
18.17
Precedente Chiudi:
$17.68
Aprire:
$17.72
Volume 24 ore:
509.11K
Relative Volume:
1.19
Capitalizzazione di mercato:
$920.72M
Reddito:
$62.02M
Utile/perdita netta:
$-45.65M
Rapporto P/E:
-19.75
EPS:
-0.92
Flusso di cassa netto:
$-9.60M
1 W Prestazione:
-2.05%
1M Prestazione:
+2.19%
6M Prestazione:
+71.25%
1 anno Prestazione:
+84.09%
Intervallo 1D:
$17.48
$18.34
Intervallo di 1 settimana:
$17.25
$18.85
Portata 52W:
$7.90
$20.33
Theravance Biopharma Inc Stock (TBPH) Company Profile
Nome
Theravance Biopharma Inc
Settore
Industria
Telefono
650-808-6000
Indirizzo
UGLAND HOUSE, SOUTH CHURCH STREET, GEORGE TOWN, GRAND CAYMAN
Confronta TBPH con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
TBPH
Theravance Biopharma Inc
|
18.17 | 895.89M | 62.02M | -45.65M | -9.60M | -0.92 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Theravance Biopharma Inc Stock (TBPH) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-12-03 | Iniziato | Oppenheimer | Outperform |
| 2025-09-12 | Iniziato | B. Riley Securities | Buy |
| 2024-08-06 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2024-04-12 | Iniziato | BTIG Research | Buy |
| 2024-01-08 | Downgrade | Evercore ISI | Outperform → In-line |
| 2022-05-23 | Iniziato | SVB Leerink | Outperform |
| 2021-11-05 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2021-09-15 | Downgrade | JP Morgan | Overweight → Underweight |
| 2021-08-25 | Downgrade | Morgan Stanley | Overweight → Underweight |
| 2021-08-24 | Downgrade | Cowen | Outperform → Market Perform |
| 2020-10-14 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2020-07-07 | Iniziato | JP Morgan | Overweight |
| 2020-06-15 | Iniziato | Morgan Stanley | Equal-Weight |
| 2020-05-13 | Iniziato | Cowen | Outperform |
| 2020-01-08 | Reiterato | H.C. Wainwright | Buy |
| 2019-11-06 | Aggiornamento | Robert W. Baird | Underperform → Neutral |
| 2019-10-29 | Iniziato | H.C. Wainwright | Buy |
| 2018-03-29 | Ripresa | Piper Jaffray | Overweight |
| 2017-08-17 | Iniziato | Evercore ISI | Outperform |
| 2017-06-16 | Iniziato | Cantor Fitzgerald | Overweight |
| 2017-05-11 | Reiterato | Needham | Buy |
| 2016-12-21 | Iniziato | Needham | Buy |
| 2016-11-03 | Iniziato | Piper Jaffray | Overweight |
| 2016-10-12 | Downgrade | Robert W. Baird | Neutral → Underperform |
| 2016-08-03 | Downgrade | BofA/Merrill | Neutral → Underperform |
| 2016-06-20 | Iniziato | Guggenheim | Buy |
| 2016-06-20 | Reiterato | Leerink Partners | Outperform |
| 2016-05-12 | Iniziato | Leerink Partners | Outperform |
| 2016-05-05 | Downgrade | BofA/Merrill | Buy → Neutral |
| 2015-02-03 | Aggiornamento | Robert W. Baird | Underperform → Neutral |
Mostra tutto
Theravance Biopharma Inc Borsa (TBPH) Ultime notizie
Theravance Biopharma (NASDAQ:TBPH) Stock Rating Upgraded by Wall Street Zen - MarketBeat
History Review: How Theravance Biopharma Inc. stock reacts to global recession fearsRate Hike & Scalable Portfolio Growth Methods - moha.gov.vn
Why The Narrative Around Theravance Biopharma Is Shifting After Trelegy Monetization And Strategic Review - Yahoo Finance
Camber Capital Management LP Trims Stock Position in Theravance Biopharma, Inc. $TBPH - MarketBeat
How (TBPH) Movements Inform Risk Allocation Models - news.stocktradersdaily.com
Hsbc Holdings PLC Takes Position in Theravance Biopharma, Inc. $TBPH - MarketBeat
Theravance Bio (TBPH) Down 3.7% Since Last Earnings Report: Can It Rebound? - sharewise.com
Theravance Biopharma (TBPH) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
Theravance Biopharma (TBPH) is a Great Momentum Stock: Should You Buy? - Yahoo Finance
Theravance Biopharma schedules 2026 annual meeting and hosts investor event By Investing.com - Investing.com Canada
Rhonda Farnum Sells 31,067 Shares of Theravance Biopharma (NASDAQ:TBPH) Stock - MarketBeat
Theravance Biopharma (TBPH) Price Target Increased by 28.23% to 27.25 - Nasdaq
Why Theravance Biopharma (TBPH) is a Top Growth Stock for the Long-Term - sharewise.com
Theravance Biopharma SVP Sells Shares Worth Over $582K - TradingView
VP Farnum Sells 31,067 ($582.5K) Of Theravance Biopharma Inc [TBPH] - TradingView
Does Theravance Bio (TBPH) Have the Potential to Rally 30.64% as Wall Street Analysts Expect? - Finviz
How Theravance Biopharma Inc. (0TB) stock reacts to fiscal policiesBond Market & Long-Term Safe Investment Plans - Newser
Why Theravance Biopharma Inc. (0TB) stock attracts HNW investorsJuly 2025 Price Swings & Advanced Technical Analysis Signals - Newser
Is Theravance Biopharma Inc. stock ready for breakoutEarnings Performance Report & Free Real-Time Market Sentiment Alerts - Newser
Oppenheimer Initiates Coverage of Theravance Biopharma (TBPH) with Outperform Recommendation - Nasdaq
VP Farnum Files To Sell 31,067 Of Theravance Biopharma Inc [TBPH] - TradingView
Oppenheimer Initiates Coverage on TBPH with Outperform Rating | - GuruFocus
Oppenheimer Initiates Theravance Biopharma at Outperform With $27 Price Target - marketscreener.com
Oppenheimer initiates Theravance Biopharma stock with Outperform rating - Investing.com
Oppenheimer initiates Theravance Biopharma stock with Outperform rating By Investing.com - Investing.com Canada
Market Trends: Will Theravance Biopharma Inc stock maintain momentum in 2025July 2025 Spike Watch & Consistent Return Investment Signals - moha.gov.vn
Why analysts recommend Theravance Biopharma Inc. (0TB) stockWeekly Profit Report & Growth Focused Investment Plans - Newser
Will Theravance Biopharma Inc. stock maintain momentum in 20252025 AllTime Highs & Accurate Trade Setup Notifications - Newser
Dir Broshy Sells 29,501 ($590K) Of Theravance Biopharma Inc [TBPH] - TradingView
Trading Systems Reacting to (TBPH) Volatility - news.stocktradersdaily.com
Theravance Biopharma stock hits 52-week high at 20.29 USD By Investing.com - Investing.com Nigeria
How Theravance Biopharma Inc. stock reacts to global recession fearsTrade Volume Report & Risk Managed Investment Signals - moha.gov.vn
Theravance Biopharma stock hits 52-week high at 20.29 USD - Investing.com
Aug Movers: Will Theravance Biopharma Inc. stock outperform Dow Jones index2025 Geopolitical Influence & Short-Term High Return Ideas - BỘ NỘI VỤ
Why Theravance Biopharma Inc. stock could outperform in 2025Weekly Risk Report & Daily Chart Pattern Signal Reports - BỘ NỘI VỤ
Theravance Biopharma (NASDAQ:TBPH) Shares Gap Up Following Analyst Upgrade - MarketBeat
BTIG Maintains Theravance Biopharma (TBPH) Buy Recommendation - MSN
Dir Broshy Files To Sell 29,501 Of Theravance Biopharma Inc [TBPH] - TradingView
TBPH: BTIG Raises Price Target to $40 While Maintaining Buy Rati - GuruFocus
Theravance Biopharma (NASDAQ:TBPH) Reaches New 12-Month HighHere's What Happened - MarketBeat
[Form 4] Theravance Biopharma, Inc. Insider Trading Activity - Stock Titan
CFO Sawaf Surrenders 18,627 Of Theravance Biopharma Inc [TBPH] - TradingView
TBPH insider filing: CFO tax-withholding of 18,627 shares at $17.90 - Stock Titan
VP Miller Surrenders 6,989 Of Theravance Biopharma Inc [TBPH] - TradingView
VP Grimaud Surrenders 19,024 Of Theravance Biopharma Inc [TBPH] - TradingView
VP Farnum Surrenders 9,060 Of Theravance Biopharma Inc [TBPH] - TradingView
Theravance Biopharma Inc Azioni (TBPH) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.08%
0.91%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):